Canntab Partners with Leading Surgeon to Conduct Pain Management Trial
December 14th, 2018
Exclusive, Top News
The opioid industry is expected to generate nearly $20 billion in annual revenue by 2020, but the addictive nature of the drug has doctors and patients increasingly concerned. With the legalization of cannabis across Canada and many U.S. states, there’s an opportunity to replace dangerous opioids with efficacious cannabinoids to treat chronic and acute pain. Investors may want to take a closer look at companies focused in these areas.
Canntab Therapeutics Ltd. (CSE: PILL) (FSE: TBF1) recently announced a partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, MD, to conduct a clinical trial to analyze the efficacy of cannabis as a replacement for opioids in postoperative care. The study is expected to cost about $600,000 and take between 12 and 18 months to complete. If successful, it could open the door to significant pain management markets.
Surgical Pain Management
Most patients undergoing surgery are prescribed opioids to control their postoperative pain, such as OxyContin®, Percocet®, or Vicodin®.
Opioids travel through the bloodstream to the nervous system where they attach to specialized proteins, called OP1, OP2, or OP3 receptors, on the surfaces of opiate-sensitive neurons. Through a series of cellular events and mechanisms, the linkage of opioids to these receptors produces an analgesic effect and triggers the same biochemical processes that reward people with feelings of pleasure.
The effectiveness and widespread use of opioids has created a market that could reach $18.4 billion by 2020, making it one of the most successful classes of pharmaceutical drugs.
The problem is that opioids can be very addictive. The body builds up tolerance to opioids over time, which means that greater and greater doses are required to achieve the same effects. In addition, chronic opioid use creates brain abnormalities that create withdrawal symptoms when a person tries to stop taking opioids. More than 115 people die every day from opioid overdoses in the U.S. alone, while costs have reached $78.5 billion per year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement
The legalization of cannabis across Canada and in many U.S. states has created a unique opportunity to combat the crisis by prescribing cannabis as an alternative. Unlike opioids, cannabinoids act on the body’s endocannabinoid system to generate an analgesic effect—users don’t even need to experience the high of THC. Cannabis is also far less addictive and nobody has overdosed on cannabis and died—the same cannot be said for opioids where overdose deaths are commonplace.
Canntab’s Promising Trial
Canntab Therapeutics recently launched a research partnership with Dr. Don Garbuz, MD, Head of the Division of Lower Limb Reconstruction and Oncology of the Department of Orthopaedics at the University of British Columbia. Under the terms of the agreement, the two parties aim to conduct a study to examine and quantify the efficacy of Canntab products in replacing opioids in preoperative and postoperative pain management.
Subject to approval from the University of British Columbia, the partnership will begin clinical trials at the university using Canntab tablets to treat pain after knee-replacement surgery under the direction of Dr. Garbuz. The tablets will be manufactured at FSD Pharma’s (CSE: HUGE) Coburg, Ontario facility under its partnership that was established in September, while initial upfront fees will be covered by Canntab.
Canntab’s solid oral dose delivery systems include extended release (XR), flash melt, immediate release, modified release, and bi-layered tablets that provide a variety of cannabinoid and terpenoid blends in exacting dosages. Protected by 13 patents pending in the United States and Canada, the technology could revolutionize the cannabis industry by providing more pharmaceutical-like options that have exact dosing and familiar protocols.
Canntab Therapeutics Ltd. (CSE: PILL) (FSE: TBF1) is well-positioned to offer an alternative to opioids to both combat harmful addictions and capture a meaningful portion of the multi-billion dollar market. With clinical trials underway, the company is drawing closer to commercialization while creating numerous potential catalysts for the stock.
For more information, visit the company’s website at www.canntab.ca.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://www.cannabisfn.com/legal-disclaimer
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.